PLGA 50:50 | DLG50-2E

DLG50-2E is an ester terminated Pharma / Medical Grade linear co-polymer of polycondesed DL-lactic acid and Glycolic acid OR linear co-polymer of ring opening polymerisation of DL-lactide and Glycolide in a 50:50 molar ratio and with an inherent viscosity midpoint of 0.2 dl/g.

It is supplied in the form of white coloured lyophilized powder.

Primarily utilized in parenteral formulations and medical devices. Its applications extend to tissue engineering, nanoparticle formulation and microsphere formulation, among other diverse uses.

CAS Number:
26780-50-7

Manufacturing Process:
Polycondensation

Molecular Formula:
(C3H4O2)m x (C2H2O2)n

Synonyms:
PLGA, Poly(D,L-lactic-co-glycolic) acid, Ester terminated, Poly(DL-lactide-co-glycolide), Ester terminated

Price (per Gram)

 240.00 / per Gram
Get Quote

Additional information

Former CAS Number(s)

107760-14-5, 119652-89-0, 1255770-56-9, 130953-65-0, 31213-75-9, 339986-68-4

Synonym(s)

1, 4-Dioxane-2, 5-dione copolymer, 5-dione-1-DL-3, 6-dimethyl-1, Glycolide – lactide copolymer, Glycolide-DL-lactide copolymer, Glycolide-DL-lactide polymer, Lactide – glycolide copolymer, Lactomer, Poly(DL-lactide-co-glycolide), Poly(glycolide – lactide), Poly(glycolide-co-lactide), Polyglactin

Substance Type

Biodegradable Polymer, Ester terminated, Excipient, Lactide : Glycolide 50:50, Mw 05-20 kDa, Nanoparticles, Non-Active pharmaceutical ingredient, PLGA 50:50, Inherent Viscosity 0.16 – 0.24

Applications

Drug delivery formulations

Appearance

Solubility

,

FT NMR (PROTON)

FT IR

Lactide by NMR

Glycolide by NMR

Viscosity (1% in CHCl3)

Residual monomer DL-Lactide

Residual monomer Glycolide

Acid number

Heavy metal

Sulphated Ash

TAMC

TYMC

Bacterial Endotoxins

Self life

Molecular Weight

7,000 – 17,000 da

End Group

Ester terminated

Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations

Abstract: The key objective of this research work was to develop and evaluate dry powder for inhalation containing lipid polymer... Read More

SURFACE MODIFIED POLYMERIC NANOPARTICLES FOR ENHANCING DRUG DELIVERY OF METHOTREXATE IN THE BRAIN BY BLOCKING EFFLUX TRANSPORTERS

Abstract: The aim of the present study was to develop, optimize, and evaluate methotrexate containing poloxamer 407 coated polymeric nanoparticles... Read More

Human beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for the management of diabetic wounds

Abstract Diabetic wound (DW) is the most devastating complication resulting in significant mortality and morbidity in diabetic patients. The standard... Read More

Formulation and Evaluation of Pralidoxime-PLGA Microspheres as Antidote against Organophosphorus Poisioning

Abstract Objective: The objective of the present work is to formulate and evaluate Pralidoxime chloride (PAM)-controlled release microspheres using poly... Read More

A tailored solution for localized drug delivery in liver cancer treatment

ABSTRACT Adjuvant chemotherapy is highly recommended for liver cancer to enhance survival rates due to its tendency to recur frequently.... Read More

**Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma

Polymeric lipid hybrid nanoparticles (PHLNPs) are core-shell nanoparticle structures made up of polymer cores and lipid shells that have properties similar to both polymeric nanoparticles and liposomes. Methotrexate (MTX) loaded PLHNPs containing tween 80, phosphatidylcholine, poly D,... Read More

**Statistically designed vitamin D3 Encapsulated PLGA **microspheres dispersed in thermoresponsive in-situ gel for nasal delivery

Vitamin D deficiency is a cause of concern across the world. It is a fat-soluble vitamin and exhibits two molecular forms (D2 and D3). The aim of the present study is the development and optimization of vitamin D3 loaded PLGA microspheres by using Box Behnken Design. Additionally, to enhance nasal... Read More

**Evaluating the osteogenic potential of insulin-like growth factor-1 microspheres on osteoblastic activity around dental implants in patients with type 2 diabetes mellitus using bone scintigraphy: A split-mouth randomized controlled trial

Dental implants are susceptible to early failure when placed in patients diagnosed with type 2 diabetes mellitus. The osteoinductive potential of insulin-like growth factor-1 (IGF-1) has been widely investigated in animals with type 2 diabetes mellitus, but studies investigating the osteoinductive... Read More

Get Quote for PLGA 50:50 | DLG50-2E